Press Releases.

Month Year

Month Year

Investor Alerts

April 25, 2015

Late-Breaking Oral Presentation at The International Liver Congress™ (ILC 2015) Highlights RG-101's Potent, Durable and Pan-Genotypic Effects in Diverse HCV Population

-RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability-
- Photos 1
April 09, 2015

Regulus to Present Late-Breaking, Expanded RG-101 Data Set for the Treatment of HCV at The International Liver Congress™ 2015 (ILC 2015)

-Late-breaking data featured in oral presentation; three additional posters examining RG-101 pharmacokinetics, preclinical results to be presented-
- Photos 1
April 07, 2015

RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Selected as Clinical Candidate by AstraZeneca

-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca-
- Photos 1
March 25, 2015

Regulus Receives Orphan Medicinal Product Designation from the European Commission for RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome
- Photos 1
February 26, 2015

Regulus to Present at Cowen and Company 35th Annual Healthcare Conference
- Photos 1

Show per page